DLBCL
From the Journals
Poor survival with COVID in patients who have had HSCT
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
Conference Coverage
Novel ddPCR assay precisely measures CAR T-cells after infusion
Conference Coverage
Steroid complications in GVHD common, boost costs of care
Conference Coverage
CAR T-cell products shine in real-world setting, reveal new insights
Real-world CAR-T experience provides new insights for predicting outcomes in patients with DLBCL.
Conference Coverage
Chronic GVHD therapies offer hope for treating refractory disease
From the Journals
Prognostic gene signature identifies high- vs. low-risk DLBCL patients
The researchers calculated risk scores using their prognostic gene set in three additional published DLBCL studies.
Conference Coverage
Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies
Conference Coverage
Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL
Conference Coverage
CAR T for all R/R DLBCL patients: The jury is still out
Feature
Seven things to know about new lymphoma drug tafasitamab